Intra Abdominal Infection Market: By Causing Agents, By Diagnosis, Ultrasound, By Drugs, By Geography - Forecast 2016-2021

  • ID: 3974077
  • Report
  • Region: Global
  • 134 pages
  • IndustryARC
1 of 3
Intra-abdominal infections is generally a term used for a group of diseases related to abdomen. Such infections are one of the most common causes of causalities and deaths across the globe and includes infections such as peritonitis, intra-abdominal abscess, diverticulitis, appendicitis, food poisoning and pelvic inflammatory disease apart from this post-surgical infections are a major cause of intra-abdominal infections. Symptoms of intra-abdominal infections may vary depending on the anatomical location of infection and includes common symptoms like abdominal pain, chills, diarrhea, nausea, lack of appetite, fever, rectal tenderness and vomiting.

This report identifies the intra-abdominal infection market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to intra-abdominal infection market.

Globally North America dominated the market for intra-abdominal infection in 2015 with highest market share due to higher easy access to the treatments and awareness amongst citizen coupled with developed medical and healthcare establishment in the region. North America was followed by Europe and Asia-Pacific as the second and third largest regional market respectively, for intra-abdominal infection. However, Asia-Pacific is expected to be fastest growing regional segment during the period of study due to fast growing healthcare setup in the region especially in India and China along with growing awareness about the available treatments in the region.

This report on global intra-abdominal infection covers different type of causing agents of intra-abdominal infection, diagnosis methods, available drug types and market size in various geographical regions.

On the basis of causing agents of the intra-abdominal infection, this report is segmented into six major segments as follows: E. coli, Streptococci, Enterococci, Klebsiella, Pseudomonas, H. pylori
This reports is also classified on the basis of diagnosis method of intra-abdominal infection, based on this global intra-abdominal infection market is classified into four major segments as follows: Blood Tests, Abdominal X-Ray, Computed Tomography (Ct), Ultrasound
This reports is also classified on the basis of available drug class for the treatment of intra-abdominal infection, based on this global intra-abdominal infection market is classified into three major segments as follows: Anaerobic coverage (Metronidazole, Clindamycin, Chloramphenicol), Aerobic coverage (Beta lactums (Cefotaxin, Ceftriaxone, Aztreonam)), (Quinolones (Ciprofloxacine, Livofloxacine)), (Aminoglycosides, Gentamycine, Tobramycine)) and Vancomycines
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for intra-abdominal infection in each of the region.

This report identifies all the major companies operating in the global intra-abdominal infection market. Some of the major companies’ profiles in detail are as follows:

Pfizer Inc.

Merck Sharp & Dohme Corp.

Tetraphase Pharmaceuticals
AstraZeneca PLC
Merck & Co., Inc.
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Intra-Abdominal Infection – Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Intra-Abdominal Infection – Market Forces
4.1. Drivers
4.1.1. Increasing awareness and medical infrastructure in the developing nation
4.2. Restraints
4.2.1. The disease is difficult to diagnose and treat due to involvement of large number of causative agents, poor prognosis and varied symptoms
4.3. Opportunities
4.4. Challenges
4.5. Porter’s Five Forces Analysis
4.5.1. Bargaining Power of Suppliers
4.5.2. Bargaining Power of Buyers
4.5.3. Threat of New Entrants
4.5.4. Threat of Substitutes
4.5.5. Degree of Competition

5. Intra-Abdominal Infection – Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Intra Abdominal Infection Market, By Causing Agents
6.1. E. coli
6.2. Streptococci
6.3. Enterococci
6.4. Klebsiella
6.5. Pseudomonas
6.6. H. pylori

7. Intra Abdominal Infection Market, By Diagnosis
7.1. Blood Tests
7.2. Abdominal X-Ray
7.3. Computed Tomography (Ct)
7.4. Ultrasound

8. Intra Abdominal Infection Market, By Drugs
8.1. Anaerobic coverage
8.1.1. Metronidazole
8.1.2. Clindamycin
8.1.3. Chloramphenicol
8.2. Aerobic coveragee
8.2.1. Beta lactums
8.2.1.1. Cefotaxin
8.2.1.2. Ceftriaxone
8.2.1.3. Aztreonam
8.2.2. Quinolones
8.2.2.1. Ciprofloxacine
8.2.2.2. Livofloxacine
8.2.3. Aminoglycosides
8.2.3.1. Gentamycine
8.2.3.2. Tobramycine
8.3. Vancomycines

9. Intra Abdominal Infection Market, By Geography
9.1. Europe
9.1.1. Germany
9.1.2. France
9.1.3. Italy
9.1.4. Spain
9.1.5. Russia
9.1.6. U.K.
9.1.7. Rest of Europe
9.2. Asia Pacific
9.2.1. China
9.2.2. India
9.2.3. Japan
9.2.4. South Korea
9.2.5. Rest of Asia-Pacific
9.3. North America
9.3.1. U.S.
9.3.2. Canada
9.3.3. Mexico
9.4. Rest of the World (RoW)
9.4.1. Brazil
9.4.2. Rest of RoW

10. Intra Abdominal Infection – Market Entropy
10.1. Expansion
10.2. Technological Developments
10.3. Merger & Acquisitions, and Joint Ventures
10.4. Supply- Contract

11. Company Profiles (By- Introduction, Financials, Key Insights, Key Strategy, Product Portfolio, SWOT Analysis)
11.1. Pfizer Inc.
11.2. Merck Sharp & Dohme Corp.
11.3. Tetraphase Pharmaceuticals
11.4. AstraZeneca PLC
11.5. Merck & Co., Inc.
11.6. Atox Bio Inc
11.7. Aurobindo Pharma Ltd.
11.8. Teva
11.9. Dr Reddys Labs Ltd.
11.10. Bayer AG
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

12. Appendix
12.1. Abbreviations
12.2. Sources
12.3. Research Methodology
12.4. Expert Insights
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll